This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Alcobra Ltd. [ADHD], an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder, will visit the NASDAQ MarketSite in Times Square to celebrate its recent initial public offering (IPO), which occurred on May 22 on The NASDAQ Stock Market.
In honor of the occasion,
Yaron Daniely, CEO will ring the Opening Bell.
NASDAQ MarketSite – 4 Times Square – 43
rd & Broadway – Broadcast Studio
Thursday, June 6, 2013 – 9:15 a.m. to 9:30 a.m. ET
U.S. Investor Contacts: KCSA Strategic Communications Jeffrey Goldberger / Garth Russell +1 (212) 896-1249 / +1 (212) 896-1250
firstname.lastname@example.org/ email@example.comIsrael Investor Contact: Investor Relations Ltd. Moran Meir-Beres +011972-3-5167620
firstname.lastname@example.orgNASDAQ MarketSite: Christine Barna (646) 441-5310
Christine.Barna@nasdaqomx.comFeed Information: Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Facebook and Twitter:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:
For news tweets, please visit our Twitter page at:
A live webcast of the NASDAQ Opening Bell will be available at:
To obtain a hi-resolution photograph of the Market Open, please go to
http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About Alcobra Ltd. [ADHD]:
Alcobra Ltd. is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder. MG01CI has completed Phase II studies to treat Attention Deficit Hyperactivity Disorder. The company was founded in 2008 and is headquartered in Tel Aviv, Israel.